Arla Foods creates project with Morrisons, Tesco and Aldi to trial use of Bovaer
Arjuna Natural Ltd. launches Shoden, its high-potency, all-natural ashwagandha extract, at Vitafoods, Geneva.
This plant has been extensively used in India for centuries to reduce symptoms of anxiety and stress.
Arjuna has invested in several ongoing clinical studies of Shoden® at top research institutes. Results of the first study will be published in a few months.
Innova Market Insights reports +18% average annual growth for new product launches featuring ashwagandha as an ingredient (Global, CAGR 2013-2017).
Ashwagandha extract contains alkaloids. Some of the alkaloids are toxic and it is technically challenging to remove them and keep the product safe to use.
Arjuna developed a new, proprietary method of purification, based on traditional Indian processes, that targets and removes only toxic alkaloids, while retaining the beneficial bioactive ones.
“Results following tests of Shoden® in multiple trials at Arjuna’s R&D lab proved the ability of this gentle process to ensure a pure, safe-to-use ashwagandha,” says Benny Antony, PhD, Joint Managing Director for Arjuna.
Activity of each product batch is guaranteed tested and confirmed by in vivo testing.
Patent protected Shoden has a high amount of glycowithanolides in comparison to other ashwagandha extracts in the market.
“We identified specific locations/farms in India for the cultivation of ashwagandha under our supervision and harvested once the crop reaches optimal growth level that allow us to provide supplement manufacturers a consistent, potent ingredient,” adds Antony.
“Arjuna also maintains transparency and traceability from-farm to supplement to guarantee a stable, safe supply.”
Arjuna’s production processes and products meet market-specific regulations worldwide.
A GMP-certified, SAP-driven company, Arjuna has achieved international certifications including ISO22000, Kosher and Halal.
Arjuna continues to engage in research and development, with continuing scientific validation of its novel product line through advanced clinical studies.